2025 Q4 -tulosraportti
Vain PDF
87 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 t sittenIf Eli Lilly is Circio's Big pharma partner ( as many believe..) and the collaboration exceeds all expectations ( ref Wiklund) it could lead to licensing. But, if Eli Lilly considers it, don't you think they will want to own this technology themselves?
BP is de-risking circvec as we speak, in-vivo testing is ongoing. We just don't get to know the results as early as BP. When the acquisition announcement comes, then we know that it went well. 
·11 t sittenIf someone hasn't understood what Circio is, I can try to explain it. They have no sales of products or other fixed revenues. A deficit is naturally still expected in the research phase as there are no revenues. Financing mainly comes from share issues and investors. Future revenues are dependent on license agreements, partnerships, or products eventually being commercialized. Circio is a typical development biotech company, and its value lies in future results, or how much faith one has in their team and research. So, there will be no "clinking coins in the till" until we get results from research, clinical data, patents, partnerships with larger pharmaceutical companies, or opportunities for future commercialization. The fact that Circio has reassuring financing for the future is a security for us as shareholders. Those who believe this will skyrocket tomorrow are probably wrong. I have been involved since 2010 when it was Targovax and have more and more faith in the research/team and the platform they are developing. Stock prices on the exchange are much psychology and nerves. Unfortunately, it also turns out that many invest money they need for other things. When investments then go down, it is often these people who sell to cut their losses. Much of this affects the price. I have huge faith in the company, but one must remember that there is always a risk. Happy summer 🌞👍
·12 t sitten"Atsena selects clinical candidate ATSN-401 for Stargardt disease. Atsena Therapeutics Inc. has selected a lead clinical candidate for ATSN-401, a gene therapy for Stargardt disease. ATSN-401 is now progressing in IND-enabling studies." (BioWorld, July 10, 2026) This issue from July 10, 2026, contains news that is at the core of Circio's original biology, in addition to two significant macro and cellular trends that directly underpin the market they operate in. Here is the objective analysis for a positioned shareholder: 1. Atsena news: Gene therapy in the eye (Stargardt disease) Atsena Therapeutics has selected its lead candidate (ATSN-401) to start regulatory safety studies (IND-enabling) before testing in humans with Stargardt disease. Stargardt disease is a rare, hereditary eye disease that leads to blindness, and it is caused by mutations in a specific gene (ABCA4) in the retina. No competition, Atsena does not compete with Circio. Atsena is developing a specific gene therapy for one particular rare diagnosis. The value for Circio lies in the delivery problem Atsena must solve, which highlights why circular RNA is needed: The problem with large genes (Atsena's challenge): The gene that causes Stargardt disease (ABCA4) is enormously large. Traditional viral vectors (AAV), which Atsena uses, have extremely limited space inside. Fitting large gene recipes into a regular virus is the biotech industry's answer to packing an entire moving load into a small passenger car. Atsena must use complicated "dual-vector" systems (splitting the gene into two viruses that must fuse inside the cell) to make it work. Circio's unique advantage: It is precisely this bottleneck that Circio's circVec platform addresses. By using circular RNA, one can pack far more compact genetic material that provides more powerful and longer-lasting protein expression. When companies like Atsena pave the way in the regulatory landscape for retinal diseases, it increases the value of Circio's more compact in vivo engine for the eye (where data for wet AMD is, as known, being finalized during Q3). 2. ARPA-H injects 160 million dollars into In Vivo precision medicine The US government's health and research agency, ARPA-H, has launched the THRIVE program with a framework of 160 million dollars (approx. 1.7 billion NOK) over 5 years. The purpose is explicit: to accelerate the development of in vivo genetic medicines for rare hereditary diseases. Why this is important for Circio shareholders: Capital is moving where Circio stands: That US health authorities earmark billions specifically for in vivo precision genetic medicines shows exactly where the political, medical, and financial center of gravity lies in the second half of 2026. It validates Circio's strategic pivot: It is in vivo delivery (doing the job directly inside the patient's body) that is the future, not the old, expensive ex vivo methods. 3. Fate Therapeutics receives IND approval for CAR-T against autoimmune diseases Fate Therapeutics has received FDA approval to start clinical trials with a new CAR-T product (FT-839) targeting CD19/CD38 for autoimmune diseases. Why this is important for Circio shareholders: CAR-T is no longer just for cancer: This is a massive commercial trend. CAR-T cell therapy is expanding rapidly out of cancer clinics and into the gigantic market for autoimmune diseases (such as Lupus, arthritis, etc.). Enlarges Circio's potential pie: Since Circio recently secured three parallel CAR-T collaborations (Acuitas, GenAssist, and Tcelltech) to validate its circVec engine in T-cells, this trend means that the final market their platform can be licensed to is about to double. They are no longer just aiming for a cancer market, but for an entire wave of autoimmune treatments. The economic picture Today's newsletter from BioWorld contains no red flags or direct competition threatening Circio. On the contrary, the issue confirms three things: The industry is struggling with delivery capacity in the eye (Atsena), US government billions are being channeled into in vivo gene therapy (ARPA-H), and the CAR-T market is expanding tremendously into autoimmune diseases (Fate). For a platform company like Circio, this means that the commercial relevance of the technology is increasing across all three axes, while they process their own in vivo data for eye and CNS programs in the coming months. Today's valuation on the Oslo Stock Exchange does not account for this broad, global sector tailwind.
Stargardts has been in partner Entos Pharma's pipeline for a long time without Entos seeming to have made any progress, neither there nor with any other of its projects. They have a PVL technology, possibly it doesn't deliver. ENTOS entered into an agreement with Lilly in 2022 and nothing has been reported there either. It was in CNS. Possibly there was contact between Lilly and Circio via that collaboration? Who knows. The feasibility study is ongoing in CNS but in AAV, and then I don't think Entos is involved there. But interesting to see the delivery challenges here and how relevant a field Circio is in now. Perfect timing.- ·12 t sittenWhat is a querulous person? Does anyone have access to AI?
·15 t sittenThe trend for this is downward, even a 5-year-old can see that. But one can easily imagine that suddenly there will be a crazy news, a breakthrough or an acquisition, which lifts the price from 7 to 70… or even to 700. But on the other hand, one can imagine anything. Until then, we just have to look at the cold facts: The trend is downward 📉 🦀💨Hope can certainly be a strategy. It has worked for thousands of years. It has made people multi-millionaires. Or at least made the church a multi-millionaire. But this time it's different!!! We know what we have 🦀💨
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
87 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 t sittenIf Eli Lilly is Circio's Big pharma partner ( as many believe..) and the collaboration exceeds all expectations ( ref Wiklund) it could lead to licensing. But, if Eli Lilly considers it, don't you think they will want to own this technology themselves?BP is de-risking circvec as we speak, in-vivo testing is ongoing. We just don't get to know the results as early as BP. When the acquisition announcement comes, then we know that it went well.
- ·11 t sittenIf someone hasn't understood what Circio is, I can try to explain it. They have no sales of products or other fixed revenues. A deficit is naturally still expected in the research phase as there are no revenues. Financing mainly comes from share issues and investors. Future revenues are dependent on license agreements, partnerships, or products eventually being commercialized. Circio is a typical development biotech company, and its value lies in future results, or how much faith one has in their team and research. So, there will be no "clinking coins in the till" until we get results from research, clinical data, patents, partnerships with larger pharmaceutical companies, or opportunities for future commercialization. The fact that Circio has reassuring financing for the future is a security for us as shareholders. Those who believe this will skyrocket tomorrow are probably wrong. I have been involved since 2010 when it was Targovax and have more and more faith in the research/team and the platform they are developing. Stock prices on the exchange are much psychology and nerves. Unfortunately, it also turns out that many invest money they need for other things. When investments then go down, it is often these people who sell to cut their losses. Much of this affects the price. I have huge faith in the company, but one must remember that there is always a risk. Happy summer 🌞👍
- ·12 t sitten"Atsena selects clinical candidate ATSN-401 for Stargardt disease. Atsena Therapeutics Inc. has selected a lead clinical candidate for ATSN-401, a gene therapy for Stargardt disease. ATSN-401 is now progressing in IND-enabling studies." (BioWorld, July 10, 2026) This issue from July 10, 2026, contains news that is at the core of Circio's original biology, in addition to two significant macro and cellular trends that directly underpin the market they operate in. Here is the objective analysis for a positioned shareholder: 1. Atsena news: Gene therapy in the eye (Stargardt disease) Atsena Therapeutics has selected its lead candidate (ATSN-401) to start regulatory safety studies (IND-enabling) before testing in humans with Stargardt disease. Stargardt disease is a rare, hereditary eye disease that leads to blindness, and it is caused by mutations in a specific gene (ABCA4) in the retina. No competition, Atsena does not compete with Circio. Atsena is developing a specific gene therapy for one particular rare diagnosis. The value for Circio lies in the delivery problem Atsena must solve, which highlights why circular RNA is needed: The problem with large genes (Atsena's challenge): The gene that causes Stargardt disease (ABCA4) is enormously large. Traditional viral vectors (AAV), which Atsena uses, have extremely limited space inside. Fitting large gene recipes into a regular virus is the biotech industry's answer to packing an entire moving load into a small passenger car. Atsena must use complicated "dual-vector" systems (splitting the gene into two viruses that must fuse inside the cell) to make it work. Circio's unique advantage: It is precisely this bottleneck that Circio's circVec platform addresses. By using circular RNA, one can pack far more compact genetic material that provides more powerful and longer-lasting protein expression. When companies like Atsena pave the way in the regulatory landscape for retinal diseases, it increases the value of Circio's more compact in vivo engine for the eye (where data for wet AMD is, as known, being finalized during Q3). 2. ARPA-H injects 160 million dollars into In Vivo precision medicine The US government's health and research agency, ARPA-H, has launched the THRIVE program with a framework of 160 million dollars (approx. 1.7 billion NOK) over 5 years. The purpose is explicit: to accelerate the development of in vivo genetic medicines for rare hereditary diseases. Why this is important for Circio shareholders: Capital is moving where Circio stands: That US health authorities earmark billions specifically for in vivo precision genetic medicines shows exactly where the political, medical, and financial center of gravity lies in the second half of 2026. It validates Circio's strategic pivot: It is in vivo delivery (doing the job directly inside the patient's body) that is the future, not the old, expensive ex vivo methods. 3. Fate Therapeutics receives IND approval for CAR-T against autoimmune diseases Fate Therapeutics has received FDA approval to start clinical trials with a new CAR-T product (FT-839) targeting CD19/CD38 for autoimmune diseases. Why this is important for Circio shareholders: CAR-T is no longer just for cancer: This is a massive commercial trend. CAR-T cell therapy is expanding rapidly out of cancer clinics and into the gigantic market for autoimmune diseases (such as Lupus, arthritis, etc.). Enlarges Circio's potential pie: Since Circio recently secured three parallel CAR-T collaborations (Acuitas, GenAssist, and Tcelltech) to validate its circVec engine in T-cells, this trend means that the final market their platform can be licensed to is about to double. They are no longer just aiming for a cancer market, but for an entire wave of autoimmune treatments. The economic picture Today's newsletter from BioWorld contains no red flags or direct competition threatening Circio. On the contrary, the issue confirms three things: The industry is struggling with delivery capacity in the eye (Atsena), US government billions are being channeled into in vivo gene therapy (ARPA-H), and the CAR-T market is expanding tremendously into autoimmune diseases (Fate). For a platform company like Circio, this means that the commercial relevance of the technology is increasing across all three axes, while they process their own in vivo data for eye and CNS programs in the coming months. Today's valuation on the Oslo Stock Exchange does not account for this broad, global sector tailwind.Stargardts has been in partner Entos Pharma's pipeline for a long time without Entos seeming to have made any progress, neither there nor with any other of its projects. They have a PVL technology, possibly it doesn't deliver. ENTOS entered into an agreement with Lilly in 2022 and nothing has been reported there either. It was in CNS. Possibly there was contact between Lilly and Circio via that collaboration? Who knows. The feasibility study is ongoing in CNS but in AAV, and then I don't think Entos is involved there. But interesting to see the delivery challenges here and how relevant a field Circio is in now. Perfect timing.
- ·12 t sittenWhat is a querulous person? Does anyone have access to AI?
- ·15 t sittenThe trend for this is downward, even a 5-year-old can see that. But one can easily imagine that suddenly there will be a crazy news, a breakthrough or an acquisition, which lifts the price from 7 to 70… or even to 700. But on the other hand, one can imagine anything. Until then, we just have to look at the cold facts: The trend is downward 📉 🦀💨Hope can certainly be a strategy. It has worked for thousands of years. It has made people multi-millionaires. Or at least made the church a multi-millionaire. But this time it's different!!! We know what we have 🦀💨
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
87 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·11 t sittenIf Eli Lilly is Circio's Big pharma partner ( as many believe..) and the collaboration exceeds all expectations ( ref Wiklund) it could lead to licensing. But, if Eli Lilly considers it, don't you think they will want to own this technology themselves?BP is de-risking circvec as we speak, in-vivo testing is ongoing. We just don't get to know the results as early as BP. When the acquisition announcement comes, then we know that it went well.
- ·11 t sittenIf someone hasn't understood what Circio is, I can try to explain it. They have no sales of products or other fixed revenues. A deficit is naturally still expected in the research phase as there are no revenues. Financing mainly comes from share issues and investors. Future revenues are dependent on license agreements, partnerships, or products eventually being commercialized. Circio is a typical development biotech company, and its value lies in future results, or how much faith one has in their team and research. So, there will be no "clinking coins in the till" until we get results from research, clinical data, patents, partnerships with larger pharmaceutical companies, or opportunities for future commercialization. The fact that Circio has reassuring financing for the future is a security for us as shareholders. Those who believe this will skyrocket tomorrow are probably wrong. I have been involved since 2010 when it was Targovax and have more and more faith in the research/team and the platform they are developing. Stock prices on the exchange are much psychology and nerves. Unfortunately, it also turns out that many invest money they need for other things. When investments then go down, it is often these people who sell to cut their losses. Much of this affects the price. I have huge faith in the company, but one must remember that there is always a risk. Happy summer 🌞👍
- ·12 t sitten"Atsena selects clinical candidate ATSN-401 for Stargardt disease. Atsena Therapeutics Inc. has selected a lead clinical candidate for ATSN-401, a gene therapy for Stargardt disease. ATSN-401 is now progressing in IND-enabling studies." (BioWorld, July 10, 2026) This issue from July 10, 2026, contains news that is at the core of Circio's original biology, in addition to two significant macro and cellular trends that directly underpin the market they operate in. Here is the objective analysis for a positioned shareholder: 1. Atsena news: Gene therapy in the eye (Stargardt disease) Atsena Therapeutics has selected its lead candidate (ATSN-401) to start regulatory safety studies (IND-enabling) before testing in humans with Stargardt disease. Stargardt disease is a rare, hereditary eye disease that leads to blindness, and it is caused by mutations in a specific gene (ABCA4) in the retina. No competition, Atsena does not compete with Circio. Atsena is developing a specific gene therapy for one particular rare diagnosis. The value for Circio lies in the delivery problem Atsena must solve, which highlights why circular RNA is needed: The problem with large genes (Atsena's challenge): The gene that causes Stargardt disease (ABCA4) is enormously large. Traditional viral vectors (AAV), which Atsena uses, have extremely limited space inside. Fitting large gene recipes into a regular virus is the biotech industry's answer to packing an entire moving load into a small passenger car. Atsena must use complicated "dual-vector" systems (splitting the gene into two viruses that must fuse inside the cell) to make it work. Circio's unique advantage: It is precisely this bottleneck that Circio's circVec platform addresses. By using circular RNA, one can pack far more compact genetic material that provides more powerful and longer-lasting protein expression. When companies like Atsena pave the way in the regulatory landscape for retinal diseases, it increases the value of Circio's more compact in vivo engine for the eye (where data for wet AMD is, as known, being finalized during Q3). 2. ARPA-H injects 160 million dollars into In Vivo precision medicine The US government's health and research agency, ARPA-H, has launched the THRIVE program with a framework of 160 million dollars (approx. 1.7 billion NOK) over 5 years. The purpose is explicit: to accelerate the development of in vivo genetic medicines for rare hereditary diseases. Why this is important for Circio shareholders: Capital is moving where Circio stands: That US health authorities earmark billions specifically for in vivo precision genetic medicines shows exactly where the political, medical, and financial center of gravity lies in the second half of 2026. It validates Circio's strategic pivot: It is in vivo delivery (doing the job directly inside the patient's body) that is the future, not the old, expensive ex vivo methods. 3. Fate Therapeutics receives IND approval for CAR-T against autoimmune diseases Fate Therapeutics has received FDA approval to start clinical trials with a new CAR-T product (FT-839) targeting CD19/CD38 for autoimmune diseases. Why this is important for Circio shareholders: CAR-T is no longer just for cancer: This is a massive commercial trend. CAR-T cell therapy is expanding rapidly out of cancer clinics and into the gigantic market for autoimmune diseases (such as Lupus, arthritis, etc.). Enlarges Circio's potential pie: Since Circio recently secured three parallel CAR-T collaborations (Acuitas, GenAssist, and Tcelltech) to validate its circVec engine in T-cells, this trend means that the final market their platform can be licensed to is about to double. They are no longer just aiming for a cancer market, but for an entire wave of autoimmune treatments. The economic picture Today's newsletter from BioWorld contains no red flags or direct competition threatening Circio. On the contrary, the issue confirms three things: The industry is struggling with delivery capacity in the eye (Atsena), US government billions are being channeled into in vivo gene therapy (ARPA-H), and the CAR-T market is expanding tremendously into autoimmune diseases (Fate). For a platform company like Circio, this means that the commercial relevance of the technology is increasing across all three axes, while they process their own in vivo data for eye and CNS programs in the coming months. Today's valuation on the Oslo Stock Exchange does not account for this broad, global sector tailwind.Stargardts has been in partner Entos Pharma's pipeline for a long time without Entos seeming to have made any progress, neither there nor with any other of its projects. They have a PVL technology, possibly it doesn't deliver. ENTOS entered into an agreement with Lilly in 2022 and nothing has been reported there either. It was in CNS. Possibly there was contact between Lilly and Circio via that collaboration? Who knows. The feasibility study is ongoing in CNS but in AAV, and then I don't think Entos is involved there. But interesting to see the delivery challenges here and how relevant a field Circio is in now. Perfect timing.
- ·12 t sittenWhat is a querulous person? Does anyone have access to AI?
- ·15 t sittenThe trend for this is downward, even a 5-year-old can see that. But one can easily imagine that suddenly there will be a crazy news, a breakthrough or an acquisition, which lifts the price from 7 to 70… or even to 700. But on the other hand, one can imagine anything. Until then, we just have to look at the cold facts: The trend is downward 📉 🦀💨Hope can certainly be a strategy. It has worked for thousands of years. It has made people multi-millionaires. Or at least made the church a multi-millionaire. But this time it's different!!! We know what we have 🦀💨
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt